NeuroHope Therapeutics: Neuroscience Startup Selected for Drive Accelerator Program

SOUTH CAROLINA – September 30, 2025 – NeuroHope Therapeutics Inc. is a pharmaceutical company co-founded by Clemson University’s bioengineering faculty. NeuroHope specializes in developing nanotherapeutics that can locally deliver drugs to damaged, diseased or degenerating regions of the central nervous system (CNS). Each year, acute spinal cord injury (SCI) impacts approximately 17,000 new patients in the United States and 250-500,000 worldwide, while acute traumatic brain injury (TBI) affects approximately 2.5 million people in the United States and 10-60 million worldwide. Currently, there is no FDA-approved therapy for these patients. Therefore, NeuroHope’s goal is to develop nanotherapeutics that reduce neuroinflammation, mitigate progressive neurodegeneration, increase functional recovery and improve quality of life for people who are living with SCI and TBI.

Solutions

Patent care following CNS trauma, such as SCI and TBI, consists of management and rehabilitation. While the drug rolipram has potential therapeutic benefit for both SCI and TBI, its clinical translation has been limited by challenges with solubility and adverse side effects from high systemic doses. NeuroHope Therapeutics Inc. has developed a proprietary graft copolymer [PgP] that can:

  1. Increase the water solubility of rolipram (~7 times).
  2. Allow sustained local delivery in the CNS (over 7 days).
  3. Remain stable at room temperature over 3 months in suspension.
  4. Avoid systemic side effects such as emesis, arteritis and effects on endocrine function and hormonal balance.

Strengths

  • Patented (2 U.S. Patents: 10,232,050B1 and 11,633,355 B2) technology developed by founder.
  • Over $4.5 million in federal, state and foundation funding, including NIH, DoD, VA, SC-SCIRF and Craig H. Neilsen Foundation.
  • Over 20 peer-reviewed publications and over 70 international and national conference proceedings related to technology.
  • One single administration of nanotherapeutics elicits motor and cognitive function in rat acute SCI and TBI models.

Meet the Co-Founders

From left to right:

Ken Webb, Ph.D. | President

Jeoung Soo Lee, Ph.D. | Chief Technology Officer

Join now to enjoy expanded member benefits!

Enjoy exclusive member content, special events, savings, networking and more

Paige Durham

SCbio is pleased to welcome Paige Durham to the team as communications coordinator to creatively and effectively communicate the value of the life science association’s programs and initiatives.

Durham will be responsible for developing and distributing high-quality content across multiple communications channels to build, advance and grow South Carolina’s life sciences industry, a key business sector for economic prosperity for the Palmetto State.

“SCbio is excited to welcome Paige to our team as our new communications coordinator. Paige brings fresh ideas and a strong background in communications that will be invaluable as we continue to strengthen our engagement with our audience,” said SCbio President and CEO James Chappell. “We are confident that her skills and experience will be crucial in advancing our communication strategies and supporting our mission.”

Before joining SCbio, Durham was the Membership and Communications Manager at the South Carolina Pharmacy Association (SCPhA), where she used her photography, design and writing skills to create content tailored to pharmacy professionals. Durham’s effective communication skills guaranteed the delivery of brand-specific material that captured the eye of her audience.

During her time at SCPhA, Durham created and edited the Palmetto Pharmacist Journal, using her creative vision to showcase members, educational institutions and industry news. Her communications efforts successfully gained new followers for the organization over the course of a year, increasing brand visibility and promoting the pharmacy profession.

Durham holds a Bachelor of Science in hospitality and tourism management and a Bachelor of Science in business administration from the College of Charleston.

Tamia Sumpter

Tamia is a driven senior undergraduate Bioengineering student currently enrolled at Clemson University. With a strong foundation in her field, she has honed her skills through hands-on experience in research and development at Eli Lilly & Company. During her time in the ADME department, Tamia contributed significantly by working on siRNAs and their applications in finding In Vitro-In Vivo Correlation (IVIVC). Looking ahead, Tamia has set her sights on a promising career in law. She aspires to specialize in Intellectual Property Law, with a particular focus on serving as in-house counsel for leading medical device or pharmaceutical companies. Her enthusiasm for this role is palpable as she prepares to embark on her legal journey! She is also a proud member of the Omicron Phi chapter of Delta Sigma Theta Sorority, Inc., PEER Mentor for Clemson PEER/WiSE, and currently serves as the President of Clemson Bioengineering Organization (CBO). With her unique blend of scientific knowledge and legal interests, Tamia is poised to make a meaningful impact in the healthcare and life sciences industries.